357 related articles for article (PubMed ID: 16869111)
41. Methodology for discovery of Alzheimer's disease blood-based biomarkers.
Maes OC; Schipper HM; Chertkow HM; Wang E
J Gerontol A Biol Sci Med Sci; 2009 Jun; 64(6):636-45. PubMed ID: 19366883
[TBL] [Abstract][Full Text] [Related]
42. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.
Buerger K; Uspenskaya O; Hartmann O; Hansson O; Minthon L; Blennow K; Moeller HJ; Teipel SJ; Ernst A; Bergmann A; Hampel H
J Clin Psychiatry; 2011 Apr; 72(4):556-63. PubMed ID: 21208578
[TBL] [Abstract][Full Text] [Related]
43. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
45. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
[TBL] [Abstract][Full Text] [Related]
46. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease.
Jackson CE; Snyder PJ
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S137-43. PubMed ID: 18631990
[TBL] [Abstract][Full Text] [Related]
47. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
48. The role of neuroimaging in mild cognitive impairment.
Matsuda H
Neuropathology; 2007 Dec; 27(6):570-7. PubMed ID: 18021379
[TBL] [Abstract][Full Text] [Related]
49. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease.
Zamrini E; De Santi S; Tolar M
Neurobiol Aging; 2004; 25(5):685-91. PubMed ID: 15172748
[TBL] [Abstract][Full Text] [Related]
50. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
51. Prospects of genetic research of mild cognitive impairment.
van Duijn CM
J Intern Med; 2004 Sep; 256(3):235-9. PubMed ID: 15324366
[TBL] [Abstract][Full Text] [Related]
52. [Biomarkers of Alzheimer's disease].
Shoji M
Rinsho Shinkeigaku; 2004 Nov; 44(11):771-4. PubMed ID: 15651287
[TBL] [Abstract][Full Text] [Related]
53. Circulating biomarkers of cognitive decline and dementia.
Solfrizzi V; D'Introno A; Colacicco AM; Capurso C; Todarello O; Pellicani V; Capurso SA; Pietrarossa G; Santamato V; Capurso A; Panza F
Clin Chim Acta; 2006 Feb; 364(1-2):91-112. PubMed ID: 16139826
[TBL] [Abstract][Full Text] [Related]
54. [Mild cognitive impairment].
Perneczky R; Alexopoulos P; Kurz A
MMW Fortschr Med; 2004 Sep; 146(38):34-7. PubMed ID: 15532428
[TBL] [Abstract][Full Text] [Related]
55. Biomarkers for preclinical Alzheimer's disease.
Tan CC; Yu JT; Tan L
J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
[TBL] [Abstract][Full Text] [Related]
56. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A
Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049
[TBL] [Abstract][Full Text] [Related]
57. Utility of imaging for nutritional intervention studies in Alzheimer's disease.
de Wilde MC; Kamphuis PJ; Sijben JW; Scheltens P
Eur J Pharmacol; 2011 Sep; 668 Suppl 1():S59-69. PubMed ID: 21816137
[TBL] [Abstract][Full Text] [Related]
58. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease.
Montine TJ; Quinn JF; Milatovic D; Silbert LC; Dang T; Sanchez S; Terry E; Roberts LJ; Kaye JA; Morrow JD
Ann Neurol; 2002 Aug; 52(2):175-9. PubMed ID: 12210787
[TBL] [Abstract][Full Text] [Related]
59. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
[TBL] [Abstract][Full Text] [Related]
60. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease.
Une K; Takei YA; Tomita N; Asamura T; Ohrui T; Furukawa K; Arai H
Eur J Neurol; 2011 Jul; 18(7):1006-9. PubMed ID: 20727007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
